Neostigmine methylsulfate

Neostigmine methylsulfate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated in myasthenia gravis and has 1 investigational indication. It is grouped under the following drug class(es): Neurotransmitter agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Syntostigmin, Neostigmine methylsulphate, Proserine, Intrastigmina and Bloxiverz. Its PubChem CID is 5824.

CAS No 51-60-5
Molecular Formula C13H22N2O6S
Molecular Weight 334.39 g/mol
Synonyms [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium;methyl sulfate

Frequently Asked Questions